Clinical Trials Logo

Clinical Trial Summary

A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors

Clinical Trial Description


Study Design

NCT number NCT05199519
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Status Completed
Phase Phase 1
Start date December 13, 2021
Completion date January 19, 2023